J-Y Pierga
About
J-Y Pierga is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, J-Y Pierga has authored 53 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 31 papers in Cancer Research and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J-Y Pierga's work include Breast Cancer Treatment Studies (25 papers), Cancer Treatment and Pharmacology (19 papers) and Advanced Breast Cancer Therapies (18 papers). J-Y Pierga is often cited by papers focused on Breast Cancer Treatment Studies (25 papers), Cancer Treatment and Pharmacology (19 papers) and Advanced Breast Cancer Therapies (18 papers). J-Y Pierga collaborates with scholars based in France, Italy and United States. J-Y Pierga's co-authors include M. Marty, Véronique Dièras, H Magdelénat, Marc Espié, Anne Vincent‐Salomon, L. Mignot, Bernard Asselain, J.M. Extra, Claude Nos and Jean Paul Thiery and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.
In The Last Decade
J-Y Pierga
51 papers receiving 465 citations
Peers
J-Y Pierga
Sarah Croessmann United States
Peter L. Depowski United States
Franca De Paola Italy
Emily Pittman United States
Núria Chic Spain
Lingzhu Wen China
Jae Myeong Lee South Korea
Shamik Mitra Sweden
Yuka Inoue Japan
Citations per year, relative to J-Y Pierga J-Y Pierga (= 1×)
peers
Sarah Croessmann
Countries citing papers authored by J-Y Pierga
Since
Specialization
Citations
This map shows the geographic impact of J-Y Pierga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J-Y Pierga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J-Y Pierga more than expected).
Fields of papers citing papers by J-Y Pierga
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by J-Y Pierga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J-Y Pierga. The network helps show where J-Y Pierga may publish in the future.
Co-authorship network of co-authors of J-Y Pierga
This figure shows the co-authorship network connecting the top 25 collaborators of J-Y Pierga. A scholar is included among the top collaborators of J-Y Pierga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J-Y Pierga. J-Y Pierga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Barrios, Carlos H., Aditya Bardia, Xin Hu, et al.. (2025). 299MO DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC). ESMO Open. 10. 104871–104871.
2.
Dent, Rebecca, J-Y Pierga, Caterina Marchiò, et al.. (2024). LBA21 Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). Annals of Oncology. 35. S1213–S1214.
3.
André, Fabrice, et al.. (2024). 7P Trastuzumab deruxtecan (T-DXd) for advanced breast cancer (ABC) patients (pts), regardless of HER2 status: A phase II study with biomarkers analysis (DAISY) - update analysis with longer follow-up. ESMO Open. 9. 103016–103016.
4.
Mailliez, Audrey, Manuel Rodrigues, Paul Cottu, et al.. (2023). 214P Delphi consensus on the definition of visceral crisis in advanced breast cancer among French Breast Cancer Intergroup Unicancer (UCBG) experts. ESMO Open. 8(1). 101403–101403.
5.
André, Fabrice, et al.. (2022). 260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial. Annals of Oncology. 33. S656–S656.
6.
Pierga, J-Y, Gaëlle Pierron, Steven Ballet, et al.. (2021). 113P Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: Results from the Institut Curie’s database. Annals of Oncology. 32. S71–S71.
7.
Im, S-A., Antoinette R. Tan, André Mattar, et al.. (2021). 46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study. Annals of Oncology. 32. S40–S41.
8.
Pierga, J-Y, Étienne Brain, Roman Rouzier, et al.. (2019). Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database. Breast Cancer Research and Treatment. 178(3). 505–512.
9.
Cottu, Paul, Coraline Dubot, Laurence Venat‐Bouvet, et al.. (2017). Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial. Annals of Oncology. 28. v32–v32.
10.
Curtit, Elsa, Xavier Pivot, Julie Henriques, et al.. (2016). Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes. Annals of Oncology. 27. vi53–vi53.
11.
Lehmann‐Che, Jacqueline, Véronique Scott, Bernard Asselain, et al.. (2013). Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. British Journal of Cancer. 108(9). 1807–1809.
12.
Bonnefoi, Hervé, Khalil Zaman, Marc Debled, et al.. (2012). An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer. European Journal of Cancer. 49(2). 281–289.
13.
Vincent‐Salomon, Anne, J-Y Pierga, J Couturier, et al.. (2007). HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?. British Journal of Cancer. 96(4). 654–659.
14.
Sigal‐Zafrani, Brigitte, Guillemette Antoni, Alexia Savignoni, et al.. (2007). Are ipsilateral breast tumour invasive recurrences in young (⩽40 years) women more aggressive than their primary tumours?. British Journal of Cancer. 97(8). 1046–1052.
15.
Pierga, J-Y, H Magdelénat, Anne Vincent‐Salomon, et al.. (2003). Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. British Journal of Cancer. 89(3). 539–545.
16.
Pierga, J-Y, E. Bourstyn, Claude Nos, et al.. (1999). Detection of circulating MUC1-positive cells in breast cancer. Breast Cancer Research and Treatment. 57(1). 120.
17.
Scholl, Suzy, Philippe Beuzeboc, Adrian L. Harris, et al.. (1998). Is Primary Chemotherapy Useful for All Patients with Primary Invasive Breast Cancer?. Recent results in cancer research. 152. 217–226.
18.
Pierga, J-Y, R. Dendale, L. Feuvret, et al.. (1997). Radiothérapie des glioblastomes. Cancer/Radiothérapie. 1(3). 194–207.
19.
Dièras, Véronique, J.M. Extra, Éric Bellissant, et al.. (1996). Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.. Journal of Clinical Oncology. 14(12). 3097–3104.
20.
Pierga, J-Y, et al.. (1994). Dysgerminoma in a Pure 45,X Turner Syndrome: Report of a Case and Review of the Literature. Gynecologic Oncology. 55(3). 459–464.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sarah Croessmann Breakdown of academic impact, for papers by Peter L. Depowski Breakdown of academic impact, for papers by Franca De Paola Breakdown of academic impact, for papers by Emily Pittman Breakdown of academic impact, for papers by Núria Chic Breakdown of academic impact, for papers by Lingzhu Wen Breakdown of academic impact, for papers by Jae Myeong Lee Breakdown of academic impact, for papers by Shamik Mitra Breakdown of academic impact, for papers by Yuka Inoue